Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome

  • Ashwin Philips
  • Venkatraman RadhakrishnanEmail author
  • Prasanth Ganesan
  • T. S. Ganesan
  • Jaikumar Ramamurthy
  • Manikandan Dhanushkodi
  • T. G. Sagar
Original Article


Rasburicase is a recombinant urate oxidase enzyme approved for use in tumor lysis syndrome (TLS) and it acts by reducing serum uric acid levels. Using rasburicase at the recommended dose of 0.2 mg/kg/day for 5 days is expensive and it is not known whether this extended schedule is clinically beneficial compared to a single fixed dose of 1.5 mg. The aim of the present study was to evaluate the efficacy of single dose rasburicase 1.5 mg in prevention and management of TLS. Rasburicase is available as single use 1.5 mg vial. At our institution a single dose of rasburicase 1.5 mg irrespective of bodyweight has been used in adults and in children a dose of 0.15 mg/kg (maximum 1.5 mg) has been used since 2012 for prevention and management of TLS and subsequent doses are given based on biochemical response and clinical condition. We retrospectively analysed the case records of patients who had received rasburicase from January 2012 to January 2017. The study included 186 patients with hematological malignancies who received rasburicase. Children accounted for 56.4% (n = 105) patients and males comprised 73% (n = 135). Rasburicase was used prophylactically in 59 (31.7%) patients, for laboratory TLS in 76 patients (40.8%) and for clinical TLS in 51 (27.4%) patients. Single fixed dose rasburicase prevented laboratory/clinical TLS in 87% of the prophylactic group and prevented clinical TLS in 72% of the laboratory TLS group. None of the patients in prophylactic and laboratory TLS group developed clinical TLS. However, majority of the patients with clinical TLS required more than one dose rasburicase. Single dose of 1.5 mg (1 vial) rasburicase is efficient in preventing and managing laboratory TLS and is economically viable in resource constrained settings.


Tumor lysis syndrome Rasburicase Renal failure 


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants prior to starting the treatment.


  1. 1.
    Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127(1):3–11CrossRefGoogle Scholar
  2. 2.
    Howard SC, Jones DP, Pui C-H (2011) The tumor lysis syndrome. N Engl J Med 364(19):1844–1854CrossRefGoogle Scholar
  3. 3.
    Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL et al (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97(10):2998–3003CrossRefGoogle Scholar
  4. 4.
    Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J et al (2010) Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol 28(27):4207–4213CrossRefGoogle Scholar
  5. 5.
    Trifilio SM, Pi J, Zook J, Golf M, Coyle K, Greenberg D et al (2011) Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant 46(6):800–805CrossRefGoogle Scholar
  6. 6.
    Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutada NS (2013) Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther 38(4):301–308CrossRefGoogle Scholar
  7. 7.
    Herrington JD, Dinh BC (2015) Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients. J Oncol Pharm Pract 21(2):111–117CrossRefGoogle Scholar
  8. 8.
    Coutsouvelis J, Wiseman M, Hui L, Poole S, Dooley M, Patil S et al (2013) Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. Br J Clin Pharmacol 75(2):550–553CrossRefGoogle Scholar
  9. 9.
    Patel KS, Lau JE, Zembillas AS, Gallagher EM (2017) Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 23(5):333–337CrossRefGoogle Scholar
  10. 10.
    Latha SM, Krishnaprasadh D, Murugapriya P, Scott JX (2015) Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: a case series. Indian J Nephrol 25(2):91–94CrossRefGoogle Scholar
  11. 11.
    Antony R, Lakshmi S, Sivadas A, Jose WM, Sidharthan N, Pavithran K (2015) Efficacy of fixed low dose rasburicase in the prevention and treatment of tumor lysis syndrome. J Pharm Res 1:46CrossRefGoogle Scholar
  12. 12.
    Chiang J, Chan A, Lian T, Tay K, Quek R, Tao M et al (2011) Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review. Asia Pac J Clin Oncol 7(4):351–356CrossRefGoogle Scholar
  13. 13.
    McBride A, Lathon SC, Boehmer L, Augustin KM, Butler SK, Westervelt P (2013) Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. Pharmacotherapy 33(3):295–303CrossRefGoogle Scholar
  14. 14.
    Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB et al (2012) A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol Off J Eur Soc Med Oncol 23(6):1640–1645CrossRefGoogle Scholar
  15. 15.
    Vines AN, Shanholtz CB, Thompson JL (2010) Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann Pharmacother 44(10):1529–1537CrossRefGoogle Scholar
  16. 16.
    Jayabose S, Kumar V, Dhanabalan R, Rajan P, Rathnam K, Viswanathan TK (2015) Low-dose rasburicase in hematologic malignancies. Indian J Pediatr 82(5):458–461CrossRefGoogle Scholar
  17. 17.
    Kukkar SR, Panchal HP, Anand AS, Patel AA, Parikh SP, Shah SA (2016) Efficacy of single-dose rasburicase in the management of tumor lysis syndrome: a case series from a regional cancer center in western India. JAppl Hematol 7:136–140Google Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  1. 1.Department of Medical OncologyCancer Institute (WIA)Adyar, ChennaiIndia

Personalised recommendations